Sidney Kimmel Cancer Center LAPS Institutional Collaboration

悉尼金梅尔癌症中心 LAPS 机构合作

• 批准号: 10362619
• 负责人: Steven Cohen
• 金额: $ 39.85万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10362619
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Basic Science; Cancer Biology; Cancer Center; Catchment Area; Characteristics; Cities; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical assessments; Collaborations; Communities; Complement; County; Delaware; Discipline; Eastern Cooperative Oncology Group; Education; Faculty; Fostering; Funding Opportunities; Goals; Health; Health system; Hospitals; Incidence; Industry; Infrastructure; Institution; Knowledge; Laboratories; Laboratory Research; Lead; Leadership; Malignant Neoplasms; NCI Center for Cancer Research; NCI-Designated Cancer Center; National Clinical Trials Network; New Jersey; Oncology; Oncology Group; Outreach Research; Participant; Patients; Pennsylvania; Philadelphia; Population Heterogeneity; Population Research; Positioning Attribute; Process; Protocols documentation; Radiation Therapy Oncology Group; Research; Research Personnel; Research Priority; Role; Shapes; Site; System; Technology; Time; Translational Research; Underserved Population; United States National Institutes of Health; base; bench to bedside; cancer care; career development; community engagement; data quality; design; health equity; innovation; leadership development; member; mortality; outreach; performance site; population based; programs; rare cancer; research study; socioeconomics; symptom management

ABSTRACT The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is a NCI-designated cancer center nucleated at the Jefferson Health-Center City campus and enriched by fully integrated research components at Jefferson Health-Abington and Jefferson Health-Aria. Building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery. The Jefferson Health system has expanded over the last 3 years and now includes a system of 12 Hospitals treating more than 8,000 new cancer cases annually. The SKCC catchment area includes Philadelphia, Montgomery, and Delaware counties in Pennsylvania, and Camden County in New Jersey. Philadelphia's highly diverse population, with numerous socioeconomic, racial, and health challenges characteristic of major northeastern cities, shapes SKCC research priorities and outreach. At any given time, hundreds of research studies are underway at the cancer center, ranging from basic laboratory research to clinical assessments of new treatments to meet the needs of this diverse population. Many of these studies are collaborative, involving other cancer centers or other partners in industry and the community. The overall objective and goal of this proposal is to enable SKCC to participate as a Lead Academic Participating Site (LAPS) in the NCI National Clinical Trial Network (NCTN) Clinical Research Program. This goal will be achieved through providing scientific leadership for development and execution of NCTN trials complemented by an integrated and collaborative research program. The SKCC has an established and well supported infrastructure to nurture discoveries and processes that advance our fundamental knowledge of cancer biology and implementing them into the community. As an NCI-designated Cancer Center, SKCC addresses the cancer needs of a diverse population through integration of laboratory and population-based clinical research, engagement of the community in relevant research to identified challenges, outreach, and education regarding clinical trials. We propose the following specific aims in this LAPS application: Specific Aim 1: Deliver and enhance access to the most advanced cancer care through participation and dissemination of NCTN initiatives including trials for rare tumors across the SKCC. Specific Aim 2: Promote and support the scientific leadership within the NCTN. Specific Aim 3: To foster junior faculty investigators' career development through NCTN participation in both NCTN/NCI committee engagement and as key contributors to conceptual protocol designs.

抽象的 悉尼金梅尔癌症中心 (SKCC) 的总体目标是利用研究专业知识来减少 大费城及其他地区癌症的总体发病率、负担和死亡率。 SKCC的目标是 通过基础、临床、 和人口研究学科。 SKCC 是 NCI 指定的癌症中心，核心位于杰斐逊医院 健康中心城市校区，并通过杰斐逊健康阿宾顿完全集成的研究组件而丰富 和杰斐逊健康-阿里亚。凭借这些优势，SKCC 专注于满足集水区需求 通过培育跨学科研究、扩大创新研究能力、扩大覆盖范围 和临床研究进入社区，并加快从实验室到临床发现的步伐。这 Jefferson Health 系统在过去 3 年里不断扩大，目前包括 12 家医院 每年治疗超过 8,000 例新癌症病例。 SKCC 服务范围包括费城、 宾夕法尼亚州的蒙哥马利县和特拉华县，以及新泽西州的卡姆登县。费城的 人口高度多样化，主要人口面临众多社会经济、种族和健康挑战 东北城市，确定 SKCC 的研究重点和推广范围。在任何特定时间，都会有数百项研究 癌症中心正在进行研究，从基础实验室研究到临床评估 新的治疗方法可以满足不同人群的需求。其中许多研究是合作性的，涉及 其他癌症中心或行业和社区的其他合作伙伴。本次活动的总体目标和目标 提案旨在让 SKCC 作为主要学术参与中心 (LAPS) 参与 NCI 国家研究中心 临床试验网络 (NCTN) 临床研究计划。这一目标将通过提供 NCTN 试验的开发和执行的科学领导力，辅以综合和 合作研究计划。 SKCC 拥有完善且支持良好的基础设施来培养 推进我们癌症生物学基础知识并加以实施的发现和过程 进入社区。作为 NCI 指定的癌症中心，SKCC 致力于满足不同人群的癌症需求 通过整合实验室和基于人群的临床研究、参与 社区参与相关研究，以确定有关临床试验的挑战、推广和教育。我们 在此 LAPS 应用程序中提出以下具体目标： 具体目标 1：提供并增强对 通过参与和传播 NCTN 举措（包括试验）来提供最先进的癌症护理 跨越 SKCC 的罕见肿瘤。具体目标 2：促进和支持科学领导力 NCTN。具体目标 3：通过 NCTN 的参与促进初级教师研究者的职业发展 参与 NCTN/NCI 委员会的工作，并作为概念协议设计的关键贡献者。